https://biotechmorning.com/news/argenx-sjogrens-trial-failure Biotech Morning en 2026-10-20T14:12:55.140Z Argenx Just Hit a Wall Nobody Saw Coming https://biotechmorning.com/news/lilly-metis-ai-lnp-delivery-deal Biotech Morning en 2026-10-20T14:12:09.297Z Lilly Just Bet $1.1 Billion That AI Can Solve Biotech's Delivery Problem https://biotechmorning.com/news/merck-kgaa-bio-techne-acquisition-biggest-deal Biotech Morning en 2026-10-20T14:11:21.289Z Merck KGaA Just Made Its Biggest Bet in a Decade. Here's What It Bought. https://biotechmorning.com/news/china-biopharma-technology-export-restrictions Biotech Morning en 2026-10-20T14:10:32.870Z China Just Drew a Line Around Its Best Biotech Secrets https://biotechmorning.com/news/tezepelumab-crossing-eoe-phase-3-results Biotech Morning en 2026-10-20T14:09:51.923Z The Asthma Drug Crashing Dupixent's Biggest Party https://biotechmorning.com/news/eyepoint-wet-amd-double-failure-layoffs Biotech Morning en 2026-10-20T14:09:03.827Z EyePoint's Wet AMD Drug Failed Twice. Then Came the Pink Slips. https://biotechmorning.com/news/dostarlimab-rectal-cancer-fda-approval Biotech Morning en 2026-10-20T14:08:18.776Z The Cancer That Disappeared in Every Single Patient https://biotechmorning.com/news/merck-kgaa-silence-therapeutics-acquisition Biotech Morning en 2026-10-20T14:07:34.760Z Merck KGaA Just Paid $1.3 Billion to Silence a Gene